Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338191 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL4291 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL4687 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL3119262 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL8192290 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5835621 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL8532996 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL6374631 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL27504027 | 0.98 | GRM5 (0.48) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5196221 | 0.91 | GRM5 (0.57) | GRM5CA2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541375-B1 | FACTOR XIIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3541375-B1 | FACTOR XIIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-10875851-B2 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875851-B2 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190352294-A1 | Factor XIIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190352294-A1 | Factor XIIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3541375-A1 | FACTOR XIIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10202371-B2 | Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors | NOVARTIS AG (CH) | 2019-02-12 | — | — | US | disclosed |
| US-10202371-B2 | Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors | NOVARTIS AG (CH) | 2019-02-12 | — | — | US | disclosed |
| WO-2018093695-A1 | FACTOR XIIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| EP-1862457-A2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SmithKline Beecham Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| US-6177450-B1 | MIXTURE OF PERHYDROISOINDENE COMPOUND AND BENEZAMIDE COMPOUND | AVENTIS PHARMA S.A. | 2001-01-23 | — | — | US | disclosed |
| US-5739351-A | NEUROKININ A ANTAGONISTS | RHONE-POULENC RORER S.A. (FR) | 1998-04-14 | — | — | US | disclosed |
| US-5631279-A | ANTAGONISTS OF NEUROKININ A | RHONE-POULENC RORER, S.A. (FR) | 1997-05-20 | — | — | US | disclosed |
| US-5508433-A | Derivatives of perhydroisoindole and preparation thereof | RHONE-POULENC RORER S.A. (FR) | 1996-04-16 | — | — | US | disclosed |
| US-5451601-A | Perhydroisoindole derivatives and pharmaceutical compositions containing them | RHONE-POULENC RORER S.A. (FR) | 1995-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875851-B2 | Factor XIIa inhibitors | F11, F13B, SERPINC1 | GRM5 4456/4885CA2 1180/4885SLC6A2 4702/4885 |
| US-10202371-B2 | Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors | PIK3CA, PIK3CD, PIK3CB | GRM5 2373/4885CA2 3858/4885SLC6A2 4782/4885 |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | GRM5 83/4885CA2 1808/4885SLC6A2 3123/4885 |
| US-20190352294-A1 | Factor XIIa Inhibitors | F11, F13B, SERPINC1 | GRM5 4456/4885CA2 1180/4885SLC6A2 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.